19-28z CAR T Cells Induce High Complete Response Rate in Acute B Leukemia

Share this content:
CD-19 targeted 19-28z chimeric antigen receptor-modified T cells induced a complete response rate in B-ALL.
CD-19 targeted 19-28z chimeric antigen receptor-modified T cells induced a complete response rate in B-ALL.

CHICAGO—CD-19 targeted 19-28z chimeric antigen receptor (CAR)-modified T cells induced a high complete response rate in patients with relapsed or refractory acute B lymphoplastic leukemia (B-ALL), long-term outcome data from a phase 1 study presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting has shown.

These findings “strongly support” use of 19-28z CAR T cells in this population, which has a “dismal prognosis,” and warrants a phase 2 trial, said Jae Hong Park, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, NY.

In the phase 1 trial, “patients with relapsed or refractory CD19+ B-ALL underwent leukapheresis, and T cells were transduced with a gamma retroviral vector encoding a CAR construct composed of anti-CD19 scFv linked to CD28 and CD3ζ signaling domains (19-28z),” he reported. Relapse after allogenic hematopoietic stem cell transplantation (HSCT) was allowed.

All patients received conditioning chemotherapy followed by 1–3x106 19-28z CAR T cells/kg.

Patients with active CNS disease, active graft-versus-host disease requiring immunosuppressants, or significant heart disease were excluded from the study.

Of the 39 patients treated, 38 were evaluable for response assessment with 1 month or longer follow-up. Median age was 45 years (range: 22-74 years) and 76% were male. A total of 13 patients (33%) had Philadelphia chromosome (Ph)+ T315I mutation; 14 (36%) had prior allogeneic stem cell transplant (allo-SCT); and 20 (51%) had 3 or more prior lines of therapy.

At the time of CAR T cell infusion, 20 had morphologic disease (>5% blasts in bone marrow) and 18 had minimal residual disease (MRD). After 19-28z CAR T cell infusion, 16 of the 20 patients with morphologic disease (80%) and 17 of the 18 patients with minimal residual disease (94%) were in complete remission (CR), for an overall CR rate of 87% (33 of 38 patients).

RELATED: First-in Human FLT3/Axl Inhibitor Study Shows High Degree of Clinical Activity for Leukemia

Of the 32 patients evaluable with minimal residual disease, the minimal residual disease-negative CR rate was 81%. Median time to CR was 23.0 days (range: 8-46 days). Thirteen patients underwent allo-SCT following CAR T cell infusion.

As of the March 30, 2015, median follow-up was 5.6 months (range: 1.0-38+ months) and median duration of response or relapse-free survival was 5.3 months (95% CI: 3,9).

Dr. Park said depth of response, as denoted by MRD negativity, is correlated with overall survival (OS). The 6-month OS rate for all patients was 59% (95% CI: 39,74); median OS was 8.5 months. Among MRD patients, median OS was 10.8 months; OS rate was 75% (95% CI: 50,89).

Among those who had allo-SCT following CAT T cell infusion, median OS was 9.9 months compared with 8.5 months for those who did not undergo allo-SCT (P=0.5). Severe cytokine release syndrome, which correlates with disease burden and required vasopressors or mechanical ventilation for hypoxia, was observed in 9 patients and was effectively managed with IL-6R inhibitor and/or corticosteroids.

Reference

  1. Park JH, Riviere I, Wang X, et al. Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. J Clin Oncol. 2015;33:(suppl; abstr 7010).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs